NFE2L2 and lung cancer: A combination of CRISPR-Cas9-based genetic screening and metabolomic profiling by Romero et al. showed that KEAP1/NFE2L2-mutant lung cancer relies on increased glutaminolysis, and pharmacological inhibition of glutaminase exerts therapeutic efficacy 19.